Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2022-12-06 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
上市公司独立董事提名人声明（刘光福）
Board/Management Information Classification · 95% confidence The document is a formal statement from a company's board nominating an individual as an independent director candidate. It includes detailed declarations about the nominee's qualifications, compliance with various regulatory requirements, and absence of conflicts or disqualifications. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management changes, specifically the nomination of a new independent director. Therefore, this document fits the category of Board/Management Information (MANG). The document length is sufficient and the content is substantive, not just an announcement or certification.
2022-12-06 Chinese
上市公司独立董事候选人声明（耿小平）
Board/Management Information Classification · 95% confidence The document is a detailed declaration by an independent director candidate of Anhui Anke Biotechnology (Group) Co., Ltd. It contains statements about the candidate's qualifications, compliance with laws and regulations, and independence criteria. There are no financial statements, earnings data, or report summaries. The content is focused on governance and compliance related to board membership qualifications. This type of document fits best under Board/Management Information (MANG), as it relates to announcements or declarations about board members or candidates.
2022-12-06 Chinese
独立董事关于相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding the nomination and election of the company's board members for the upcoming term. It discusses compliance with laws and regulations related to board nominations and confirms the qualifications of the proposed directors. There is no financial data, no mention of financial results, no earnings, no audit, no capital changes, or other report types. The document is related to board/management information, specifically about board member nominations and governance matters. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short but contains substantive content about board nominations, not just an announcement or a report publication notice.
2022-12-06 Chinese
关于召开2022年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2022 third extraordinary general meeting of shareholders for Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It includes information about the meeting date, voting procedures (including cumulative voting for board and supervisory candidates), registration details, and attachments such as proxy forms and voting instructions. The content focuses on the announcement and procedural details for the shareholder meeting, including election of directors and supervisors, but does not contain any voting results or financial data. This matches the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings. It is not an announcement of voting results (DVA), nor a full annual or interim report, nor a management or earnings report. The document length and detail confirm it is the solicitation/information statement itself, not just a brief announcement or regulatory filing. Therefore, the correct classification is PSI with high confidence.
2022-12-06 Chinese
独立董事候选人关于参加独立董事培训并取得独立董事资格证书的承诺函
Board/Management Information Classification · 95% confidence The document is a commitment letter from an independent director candidate regarding participation in training and obtaining a qualification certificate. It references board resolutions and regulatory rules but does not contain financial data, report content, or voting results. It is related to board/management information about a director candidate's qualifications and commitments. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report or certification, so it is not RNS or RPA.
2022-12-06 Chinese
上市公司独立董事提名人声明（陈飞虎）
Board/Management Information Classification · 95% confidence The document is a formal statement from a nominator (the company's board) regarding the nomination of an independent director candidate for the company's board. It details the qualifications, compliance with laws and regulations, and other criteria for the nominee. There is no financial data, no discussion of financial results, no voting results, no meeting materials, and no mention of report publication. The content is focused on board/management information, specifically the nomination of a board member. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is about 5,489 characters, which is consistent with a detailed nomination statement rather than a brief announcement or a full report.
2022-12-06 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.